Regulus Therapeutics Inc.
RGLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $347 | $21,152 | $122 | $459 |
| Gross Profit | -$347 | -$21,152 | -$122 | -$459 |
| % Margin | – | – | – | – |
| R&D Expenses | $35,367 | $21,007 | $18,410 | $17,794 |
| G&A Expenses | $14,673 | $9,957 | $9,829 | $10,022 |
| SG&A Expenses | $14,673 | $9,957 | $9,829 | $10,022 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$21,007 | $0 | -$459 |
| Operating Expenses | $50,040 | $9,957 | $28,239 | $27,357 |
| Operating Income | -$50,040 | -$31,109 | -$28,239 | -$27,816 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,683 | $1,073 | -$83 | $9 |
| Pre-Tax Income | -$46,357 | -$30,036 | -$28,322 | -$27,807 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | -$46,358 | -$30,037 | -$28,323 | -$27,808 |
| % Margin | – | – | – | – |
| EPS | -0.82 | -1.58 | -1.86 | -3.24 |
| % Growth | 48.1% | 15.1% | 42.6% | – |
| EPS Diluted | -0.82 | -1.58 | -1.86 | -3.24 |
| Weighted Avg Shares Out | 56,346 | 18,960 | 15,260 | 8,570 |
| Weighted Avg Shares Out Dil | 56,346 | 18,960 | 15,260 | 8,570 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,841 | $1,677 | $605 | $864 |
| Interest Expense | $158 | $604 | $688 | $855 |
| Depreciation & Amortization | $347 | $227 | $122 | $459 |
| EBITDA | -$45,852 | -$30,882 | -$28,117 | -$27,357 |
| % Margin | – | – | – | – |